CVS Health Corporation (SNSE:CVS)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 103.00T +31.6% |
| Revenue (ttm) | 377.14T +7.7% |
| Net Income | 2.73T -44.5% |
| EPS | 2,134.30 -45.2% |
| Shares Out | n/a |
| PE Ratio | 37.78 |
| Forward PE | 11.86 |
| Dividend | 2,430.97 (3,091.65%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 78.63 |
| Day's Range | n/a |
| 52-Week Range | 51.86 - 80.50 |
| Beta | n/a |
| RSI | 100.00 |
| Earnings Date | Aug 5, 2026 |
About CVS Health
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individu... [Read more]
Financial Performance
In 2025, CVS Health's revenue was $399.83 billion, an increase of 7.87% compared to the previous year's $370.66 billion. Earnings were $1.77 billion, a decrease of -61.68%.
Financial numbers in USD Financial StatementsNews
CVS Health price target raised to $103 from $102 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on CVS Health (CVS) to $103 from $102 and keeps an Overweight rating on the shares. The firm is constructive
CVS Health price target raised to $92 from $88 at Deutsche Bank
Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $92 from $88 and keeps a Buy rating on the shares.
CVS Health price target raised to $107 from $90 at RBC Capital
RBC Capital raised the firm’s price target on CVS Health (CVS) to $107 from $90 and keeps an Outperform rating on the shares. The company reported a strong Q1 beat
CVS Health price target raised to $105 from $100 at Evercore ISI
Evercore ISI raised the firm’s price target on CVS Health (CVS) to $105 from $100 and keeps an Outperform rating on the shares.
CVS Health price target raised to $102 from $98 at Truist
Truist raised the firm’s price target on CVS Health (CVS) to $102 from $98 and keeps a Buy rating on the shares. The company reported strong Q1 results while its
CVS Health price target raised to $101 from $93 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on CVS Health (CVS) to $101 from $93 and keeps an Overweight rating on the shares post the Q1 report. CVS
CVS Health price target raised to $100 from $95 at BofA
BofA raised the firm’s price target on CVS Health (CVS) to $100 from $95 and keeps a Buy rating on the shares after the company reported a Q1 beat with
CVS Health price target raised to $100 from $97 at UBS
UBS raised the firm’s price target on CVS Health (CVS) to $100 from $97 and keeps a Buy rating on the shares. CVS delivered a strong Q1 beat with improved
CVS Health reports Q1 adjusted EPS $2.57, consensus $2.21
Reports Q1 revenue $100.43B, consensus $95.02B. The company said, “CVS Health (CVS) continues to provide what people want most from health care: a connected, convenient, cost-effective engagement expe...
CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20
Consensus $7.16. Raises FY26 cash flow from operations view to at least $9.5B from at least $9B. The company said, “The Company is increasing its full-year 2026 GAAP diluted EPS,
CVS Health raises FY26 revenue view to ‘at least’ $405B from ‘at least’ $400B
FY26 revenue consensus $404.95B. Raises FY26 adjusted operating income view to $15.53B-$15.87B from $15.07B-$15.41B. Guidance taken from investor presentation slides.
CVS Health says ‘encouraged’ by Q1 performance
Says final 2027 rates for Medicare Advantage plans remain insufficient to offset underlying medical cost trends. Comments taken from Q1 earnings conference call.
CVS Health says confident in adequacy of reserves
Says ended Q1 with 3.84x leverage ratio and expects to drive further improvement by year-end. Sees 60/40 split of earnings between 1H26 and 2H26, respectively.
CVS Health Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and earnings growth, with adjusted EPS up 14% and full-year guidance raised. Segment performance was robust, especially in Health Care Benefits and value-based care, while investments in technology and regulatory adaptation remain key priorities.
CVS Profits Eclipse $2.9 Billion As Aetna Health Plan Costs Ease
CVS Health Wednesday reported first quarter net income of more than $2.9 billion as costs slowed for subscribers of the Aetna health plans the company sells.
CVS Health raises 2026 forecast after improving medical cost controls
CVS Health raised its full-year forecast on Wednesday, aided by increased first-quarter earnings in the company's pharmacy management business and strong medical cost controls in its government-spons...
CVS blows past estimates, hikes outlook as insurance business outperforms
CVS Health on Wednesday blew past first-quarter earnings and revenue estimates and raised its 2026 guidance, as its once-troubled insurance business showed improvement. All of the health-care giant's...
CVS's Results Add to Positive Momentum for Health-Insurance Industry
The company attributed much of the improvement to a turnaround at its insurance unit, Aetna.
CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57 Raising full-year 2026 guidance: GAAP diluted EPS gui...
CVS's Aetna division is the latest insurer to report improving margins and cost controls, a positive sign for the industry
CVS attributed much of the improvement to a turnaround at its insurance unit, Aetna.
CVS to drop J&J's Stelara from its main formularies
CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars over Johnson & Johnson's psoriasis drug Stelara in its most common drug lists starting July 1.
CVS Caremark expands biosimilar adoption
CVS Health (CVS) announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including changes effec...
CVS Caremark Expands Biosimilar Adoption Through Formulary Updates to Improve Affordability and Access
New changes expected to deliver significant client savings while maintaining rigorous clinical standards WOONSOCKET, R.I., May 5, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to...
Fathom Secures Strategic Investment From CVS Health Ventures to Accelerate Enterprise-Wide Autonomous Coding
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Fathom has received a strategic investment from CVS Health Ventures, the venture capital arm of CVS Health.